Immunome, Inc. IMNM
Set alert
19.59 USD +1.38 +7.58%
At close · Nov 2
19.67 +0.08 +0.41%
After hours · Nov 2, 4:19 PM ET
18.40 Day range 19.77
14.64 52-week range 30.06
- YTD
- -8.80%
- 1 year
- +21.90%
- Open
- 18.42
- Prev close
- 18.21
- Mkt cap
- 2.31B
- Vol
- 2.28M
- Avg vol
- 1.29M
- EPS
- -2.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.40
- High
- 19.77
- Forward P/E
- -7.97
- Beta
- 2.66
- Short ratio
- 10.98
- Inst. own
- 103.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 22.44
- 200-d avg
- 22.49
- 1y target
- 35.33
3M chart
Events in this range
- Aug 11, 2026Earnings: -0.65; estimate -0.51381; surprise -26.51%
- Aug 12, 2026Rating: Truist Securities · Buy → Buy
- Sep 10, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 21, 2026Rating: Alliance Global Partners · — → Buy
- Oct 1, 2026Rating: Stifel · — → Hold
- Oct 16, 2026Rating: William Blair · — → Outperform
- Oct 27, 2026Rating: Wedbush · Outperform → Outperform
Signals (12)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| RSI: Overbought | Aug 5, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 2.31B
- Enterprise value
- 1.55B
- Trailing P/E
- 0.00
- Forward P/E
- -7.97
- PEG ratio
- 0.00
- Price / book
- 4.23
- EPS (TTM)
- -2.52
- Beta
- 2.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -143.66M
- Total cash
- 520.00M
- Total debt
- 4.74M
- Return on equity
- -64.03%
- Shares outstanding
- 118.00M
- Short % of float
- 17.02%
- 50-day average
- 22.44
- 200-day average
- 22.49
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.33 +80.4% upside
Now 19.59
- Target (low)
- 24.00
- Target (mean)
- 35.33
- Target (high)
- 40.00
Ratings (0m) 17 16 buy · 1 hold · 0 sell
- Strong buy3
- Buy13
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.5976.
Financials — quick view
IMNM Revenue — quarterly 0
IMNM Net income — quarterly -73.13M
IMNM EPS — quarterly -0.65
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.60365 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.51381 | -0.65 | -0.14 | -26.51% |
| May 12, 2026 | Mar 31, 2026 | -0.60 | -0.48 | +0.12 | +20.00% |
| Mar 3, 2026 | Dec 31, 2025 | -0.59017 | -0.75 | -0.16 | -27.08% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.65 | -0.08 | -14.04% |
| Aug 6, 2025 | Jun 30, 2025 | -0.52 | -0.50 | +0.02 | +3.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 1, 2026 | Stifel | init | — | Hold |
| Sep 21, 2026 | Alliance Global Partners | init | — | Buy |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2026 | Truist Securities | main | Buy | Buy |
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunome.com
News
- Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
- Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors
- Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
- Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target
- Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026
- Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24
- Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors
- Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Your note
Sign in to keep a note on IMNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARCHAS ISAAC | Director | Sale | Aug 11, 2026 | 0 |
| BIENAIME JEAN-JACQUES | Director | Purchase | Jun 4, 2026 | 43,415 |
| HIGGINS JACK | Officer | Conversion of Exercise of derivative security | Sep 10, 2026 | 59,250 |
| HORN KINNEY | Officer | Conversion of Exercise of derivative security | Aug 3, 2026 | 0 |
| LECHLEIDER ROBERT | Officer | Stock Award(Grant) | Jul 22, 2026 | 69,805 |
| ROSETT MAX | Chief Financial Officer | Stock Award(Grant) | Jul 22, 2026 | 101,287 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17.32% | 19,676,883 | 385.47M | Jun 29, 2026 |
| FMR, LLC | 14.96% | 16,987,553 | 332.79M | Jun 29, 2026 |
| Blackrock Inc. | 7.75% | 8,805,492 | 172.50M | Jun 29, 2026 |
| State Street Corporation | 4.84% | 5,494,625 | 107.64M | Jun 29, 2026 |
| Wellington Management Group, LLP | 4.59% | 5,210,216 | 102.07M | Jun 29, 2026 |
| Redmile Group, LLC | 4.32% | 4,911,590 | 96.22M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 6.32% | 7,179,563 | 140.65M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.32% | 4,903,773 | 96.06M | Aug 30, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.44% | 3,907,378 | 76.55M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.26% | 3,703,461 | 72.55M | Jul 30, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.25% | 3,692,941 | 72.34M | Jul 30, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.99% | 3,392,151 | 66.45M | Jun 29, 2026 |